{
  "source": "PA-Notification-Radicava-ORS.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1392-3\nProgram Prior Authorization/Notification\nMedication Radicava ORS® (edaravone)\nP&T Approval Date 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nRadicava ORS is indicated for the treatment of amyotrophic lateral sclerosis (ALS).1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Radicava ORS will be approved based upon the following criterion:\na. Diagnosis of amyotrophic lateral sclerosis (ALS)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Radicava ORS will be approved based upon the following criterion:\na. Documentation of positive clinical response to Radicava ORS therapy.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class\n• Supply limits may be in place.\n4. References:\n1. Radicava ORS [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation.\nMay 2022.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Radicava ORS® (edaravone)\nChange Control\n7/2022 New program.\n7/2023 Annual review with no changes to the coverage criteria.\n7/2024 Annual review. Updated initial authorization and reauthorization to 12\nmonths.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}